Skip to content

Study · Animal study (in vivo) · 2018

4 results

Effect of a C-end rule modification on antitumor activity of thymosin α1.

Wang F, Xu C, Peng R, Li B, Shen X, Zheng H, Lao X

Biochimie8 Aug 2018Cited by 5 (Europe PMC)

PMID30096371 (opens in a new tab)DOI10.1016/j.biochi.2018.08.001 (opens in a new tab)PepBankPUB-30096371
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the B16F10 tumor growth model, Tα1 showed a slight effect on tumor growth at the dose at which Tα1-RGDR significantly inhibited growth.

    In plain wordsIn an animal tumor model, thymosin alpha‑1 had only a slight effect on tumor growth at the dose tested.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedB16F10 tumor growth with Tα1
    Study

    n: not reported in source

    B16F10 tumor growth model
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1-RGDR treatment led to significant inhibition of tumor growth at a dose at which Tα1 showed a slight effect in the B16F10 tumor growth model.
    1 context sentence
    Summary · context
    The antitumor and immunological activities of Tα1-RGDR were measured using the B16F10 tumor and immunologic suppression models.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In the B16F10 tumor growth model, the modified peptide Tα1-RGDR significantly inhibited tumor growth at a dose at which Tα1 had only a slight effect.

    In plain wordsIn an animal tumor model, a modified thymosin alpha‑1 slowed tumor growth at a dose where the unmodified peptide had only a slight effect.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseB16F10 tumor growth with Tα1-RGDR
    Study

    n: not reported in source

    B16F10 tumor growth model
    Comparator
    Tα1
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Tα1-RGDR treatment led to significant inhibition of tumor growth at a dose at which Tα1 showed a slight effect in the B16F10 tumor growth model.
    1 context sentence
    Summary · context
    The antitumor and immunological activities of Tα1-RGDR were measured using the B16F10 tumor and immunologic suppression models.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In the immunologic suppression model, Tα1-RGDR had an almost equivalent immunomodulatory effect to Tα1.

    In plain wordsIn an animal immune suppression model, the modified peptide had almost the same immune effect as thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeImmunomodulatory effect in the immunologic suppression model
    Study

    n: not reported in source

    immunologic suppression model
    Comparator
    Tα1
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In the immunologic suppression model, Tα1-RGDR shared almost equivalent immunomodulatory effect with Tα1.
    1 context sentence
    Summary · context
    The antitumor and immunological activities of Tα1-RGDR were measured using the B16F10 tumor and immunologic suppression models.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 04LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Mechanism

    By CD spectroscopy in trifluoroethanol, both Tα1-RGDR and Tα1 shared a helical conformation.

    In plain wordsIn lab tests, both the modified peptide and thymosin alpha‑1 formed a helical shape in a trifluoroethanol solution.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableHelical conformation by CD spectroscopy
    Study

    n: not reported in source

    trifluoroethanol solution
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Moreover, both Tα1-RGDR and Tα1 shared a helical conformation in the presence of trifluoroethanol based on CD spectroscopy.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.